Home > News > Close Brothers Seydler issues 'buy' recommendation for Nanostart and EUR30.8 price target
December 6th, 2010
Close Brothers Seydler issues 'buy' recommendation for Nanostart and EUR30.8 price target
Abstract:
Equity research firm Close Brothers Seydler released a report on nanotechnology investor Nanostart AG on Friday, stating a 'buy' recommendation and a price target of EUR 30.80, nearly double its last closing price.
Frankfurt-based Nanostart invests in emerging nanotechnology companies, both public and private, that span across Europe, Asia and the US. With EUR 35 million invested to date, its current portfolio consists of nine companies across a variety of industries.
"The biggest holding, MagForce, is a shining star of the portfolio, having developed a revolutionary treatment for solid tumor brain cancers. The second largest holding, ItN, is leading the way in water filtration using ceramic treated with nanotechnology," said Close Brothers.
The research firm also noted that Nanostart is partnered with the Singaporean government and works closely in a joint fund to invest in companies out of Asia, giving it a "first-mover advantage".
Source:
proactiveinvestors.com.au
Bookmark:
| Related News Press |
News and information
Beyond wires: Bubble technology powers next-generation electronics:New laser-based bubble printing technique creates ultra-flexible liquid metal circuits November 8th, 2024
Nanoparticle bursts over the Amazon rainforest: Rainfall induces bursts of natural nanoparticles that can form clouds and further precipitation over the Amazon rainforest November 8th, 2024
Nanotechnology: Flexible biosensors with modular design November 8th, 2024
Exosomes: A potential biomarker and therapeutic target in diabetic cardiomyopathy November 8th, 2024
Investments/IPO's/Splits
Daikin Industries becomes OCSiAl shareholder July 27th, 2021
INBRAIN Neuroelectronics raises over €14M to develop smart graphene-based neural implants for personalised therapies in brain disorders March 26th, 2021
180 Degree Capital Corp. Issues Second Open Letter to the Board and Shareholders of Enzo Biochem, Inc. March 26th, 2021
Nanomedicine
Exosomes: A potential biomarker and therapeutic target in diabetic cardiomyopathy November 8th, 2024
Unveiling the power of hot carriers in plasmonic nanostructures August 16th, 2024
Announcements
Nanotechnology: Flexible biosensors with modular design November 8th, 2024
Exosomes: A potential biomarker and therapeutic target in diabetic cardiomyopathy November 8th, 2024
Turning up the signal November 8th, 2024
Nanofibrous metal oxide semiconductor for sensory face November 8th, 2024
Financial Reports
Arrowhead Pharmaceuticals to Webcast Fiscal 2021 Second Quarter Results April 16th, 2021
Arrowhead Pharmaceuticals to Webcast Fiscal 2021 Second Quarter Results April 16th, 2021
Water
Taking salt out of the water equation October 7th, 2022
Nanobiotechnology
Exosomes: A potential biomarker and therapeutic target in diabetic cardiomyopathy November 8th, 2024
The mechanism of a novel circular RNA circZFR that promotes colorectal cancer progression July 5th, 2024
 |
||
 |
||
| The latest news from around the world, FREE | ||
 |
||
|
|
||
| Premium Products | ||
 |
||
|
Only the news you want to read!
Learn More |
||
 |
||
|
Full-service, expert consulting
Learn More |
||
|
|
||